"The infectious disease consequences of injection drug use place a heavy toll on entire communities and are a serious threat to the health and well-being of our nation. The estimated cost of providing health care services to persons living with chronic HCV infection is $15 billion annually.18 The average cost of a hepatitis A–related hospitalization in 2016 was $16 610, and recent hepatitis A virus outbreaks alone have cost the nation at least $270 million since 2016.19 In 2019, HIV care and treatment cost the US government more than $20 billion.20 The cost for treating HIV infections related to the Scott County outbreak is projected to be more than $100 million.21 SSPs are associated with an approximately 50% reduction in HIV and HCV incidence.18 A 2019 study in Philadelphia found that SSPs averted 10 582 HIV infections during a 10-year period. This number equates to a 1-year return on investment of $243.4 million.22 By helping reduce the economic burden of drug use and associated infections, SSPs should be considered an important partner in my Community Health and Economic Prosperity initiative, which views community health as inherently linked with economic outcomes.23"
Adams JM. Making the Case for Syringe Services Programs. Public Health Reports. 2020;135(1_suppl):10S-12S. doi:10.1177/0033354920936233